All In Biotech

NDA 220320 · Map77

Atoncy

Atomoxetine Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Mar 20, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

195

41 Phase 3, 13 recruiting

FAERS reports

2,613

2,294 serious, 1,293 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER All pediatric patients 6 years of age or older treated with atomoxetine oral solution should be monitored and observed closely for suicidal thoughts and behaviors, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes. Families and caregivers should be advised of the need for close observation and communication with the health care provider. Consider stopping atomoxetine oral solution in patients who experience emergent suicidal thoughts and behavior [see Warnings and Precautions (5.1) ] . Atomoxetine increased the risk of suicidal ideation in pediatric patients 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies [see Warnings and Precautions (5.1) ] . WARNING: SUICIDAL THOUGHTS...

What it is approved for

From the label in effect Apr 3, 2026.

Atomoxetine oral solution is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adult and pediatric patients 6 years of age and older. Atomoxetine oral solution is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with ADHD. Atomoxetine oral solution is a selective norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of ADHD in adults and pediatric patients 6 years of age and older. ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ATONCY · ATOMOXETINE HYDROCHLORIDE EQ 4MG BASE/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Atomoxetine" as an intervention, any sponsor and status, largest first.

All 195 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use786
  • drug ineffective670
  • epilepsy620
  • pain618
  • confusional state613
  • hypoaesthesia609
  • maternal exposure during pregnancy608
  • psoriatic arthropathy598
  • swelling590
  • rheumatoid arthritis589
  • abdominal pain upper588
  • systemic lupus erythematosus578

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200411
200527
20069
200725
20102
20116
201219
201317
201422
201539
201618
201721
201846
201958
202048
202175
2022147
2023197
2024445
2025928
2026453

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 480 on PubMed

Sponsor: Map77

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.